TSW
CBST

Thompson Siegel & Walmsley’s CUBIST PHARMACEUTICALS INC CBST Stock Holding History

Thompson Siegel & Walmsley’s Portfolio CBST Stock Details CBST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-3,200
Closed -$220K – 700
2013
Q4 		$220K Buy
+3,200
New +$207K 0.01% 383

Other funds holding CBST

BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Thompson Siegel & Walmsley's CBST Position: Q1 2014 in Review

Thompson Siegel & Walmsley sold out of CUBIST PHARMACEUTICALS INC (CBST) in Q1 2014, closing a stake of 3,200 shares — an estimated $220K sold.

Thompson Siegel & Walmsley first reported a position in CBST in Q4 2013 and held it in 1 quarter. The position peaked at $220K in Q4 2013. 276 funds tracked by Wall St. Rank hold CBST as of Q1 2014.

  • Thompson Siegel & Walmsley reported no remaining CUBIST PHARMACEUTICALS INC position as of Q1 2014 after selling out during the quarter.
  • Thompson Siegel & Walmsley sold 3,200 CUBIST PHARMACEUTICALS INC shares in Q1 2014, an estimated $220K.
  • Thompson Siegel & Walmsley first reported a position in CUBIST PHARMACEUTICALS INC in Q4 2013 and held it in 1 quarter.
  • Thompson Siegel & Walmsley's CUBIST PHARMACEUTICALS INC position peaked at $220K in Q4 2013.
  • 276 funds tracked by Wall St. Rank held CUBIST PHARMACEUTICALS INC as of Q1 2014.

Based on Thompson Siegel & Walmsley's 13F filing for Q1 2014, filed 8 May 2014.